TRISTAN SAAD: Open Payments
NPI 1639572837 · CHARLOTTE, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$952 in 48 payments from 16 companies in 2025. Trend: 2023 $628 · 2024 $1,459 · 2025 $952
Food & beverage: $952
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 9 | $160 |
| GlaxoSmithKline, LLC. | 6 | $114 |
| PFIZER INC. | 5 | $109 |
| Novo Nordisk Inc | 5 | $91 |
| ABBVIE INC. | 4 | $79 |
| Sumitomo Pharma America, Inc. | 3 | $76 |
| Lilly USA, LLC | 3 | $47 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Merck Sharp & Dohme LLC | 2 | $39 |
| Amgen Inc. | 2 | $35 |
Products named: SHINGRIX, GEMTESA, AIRSUPRA, PREVNAR 20, BREZTRI, Ozempic, MOUNJARO, REXULTI.
Industry payments across NC — which companies pay providers there.
